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ABSTRACT  
The identification of cancer-promoting genetic alterations is challenging 
particularly in highly unstable and heterogeneous cancers, such as esophageal 
adenocarcinoma (EAC). Here we describe a machine learning algorithm to identify 
cancer genes in individual patients considering all types of damaging alterations 
simultaneously. Analysing 261 EACs from the OCCAMS Consortium, we discover 
genes that, alongside well-known drivers, promote cancer. We confirm the 
robustness of our approach in 107 additional EACs. Unlike recurrent alterations of 
known drivers, these cancer genes are rare or patient-specific. However, they 
converge towards perturbations of well-known cancer processes. Recurrence of 
same process perturbations, rather than individual genes, divides EACs into six 
clusters differing in their molecular and clinical features. Experimentally mimicking 
the alterations of predicted cancer genes in cancer and pre-cancer cells validates 
their contribution to disease progression, while reverting their alterations reveals 
EAC acquired dependencies that can be exploited in therapy. 
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INTRODUCTION 
Genome instability enables the onset of several hallmarks of cancer with some 
acquired alterations conferring selective advantages to the mutated cells and driving 
their outgrowth and eventual dominance1. The identification of driver genes (genes 
acquiring driver alterations) is therefore critical to fully understand the molecular 
determinants of cancer and to develop precision oncology. Since driver genes are 
under positive selection during cancer progression, a reasonable assumption is that 
their mutation is observed more frequently than expected. In recent years, large-
scale cancer genomic studies have provided the required power to detect driver 
events recurring across samples with good statistical confidence2,3. However, the full 
characterisation of driver events is challenging when a cancer’s genomic landscape 
is highly variable and recurrent events are rare.  
One such cancer is esophageal adenocarcinoma (EAC), whose incidence in 
recent years has risen substantially in the western world4. EAC exhibits high 
mutational and chromosomal instability leading to widespread genetic heterogeneity. 
In over 400 EACs sequenced so far, mutations in TP53, CDKN2A, SMARCA4, 
ARID1A, SMAD4, ERBB2, MYD88, PIK3CA, KAT6A, ARID2 as well as 
amplifications of VEGFA, ERBB2, EGFR, GATA4/6, CCNE1 are the most recurrent 
driver events5,6. However, a significant fraction of patients remain without known 
genetic determinants and the number of identified drivers per sample is too low to 
fully explain the disease. Consequently, the molecular mechanisms that drive EAC 
have been difficult to characterise in full. This impacts EAC diagnosis and treatment, 
with recent phase III clinical trials of targeted agents failing to show benefits or 
reaching inconclusive results7,8.  
Here we hypothesise that, alongside the critical role of recurrent and well-
known drivers, complementary somatic alterations of other genes help cancer 
progression in individual patients. Therefore, the comprehensive characterisation of 
the full compendium of cancer drivers requires that both recurrent and rare events 
are considered. While recurrent drivers can be identified based on the frequency of 
their alterations, rare genes altered in few or even single patients are difficult to 
identify. To this aim, we develop sysSVM, an algorithm based on supervised 
machine learning that predicts cancer genes in individual patients. The rationale of 
sysSVM is that somatic alterations sustaining cancer affect genes with specific 
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properties9. It therefore uses these properties, rather than recurrence, to identify 
cancer genes.  
We apply sysSVM to 261 EACs from the UK OCCAMS Consortium, part of the 
International Cancer Genome Consortium (ICGC). We first train the classifier using 
34 features derived from the biological properties specific to known cancer genes 
and then prioritise 952 genes that, together with the known drivers, help promote 
cancer development across the whole EAC cohort. The large majority of these newly 
predicted ‘helper’ genes are rare or patient-specific but they converge towards the 
perturbation of cancer-related processes including intracellular signalling, cell cycle 
regulation, proteasome activity and Toll-like receptor signalling. We use the 
recurrence of process perturbation, rather than genes, to stratify the 261 EACs into 
six clusters that show distinct molecular and clinical features and suggest differential 
response to targeted treatment.  
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RESULTS 
The landscape of recurrent and rare EAC genes 
sysSVM applies machine learning to predict altered genes contributing to 
cancer in individual patients based on the similarity of their molecular and systems-
level properties to those of known cancer genes (Supplementary Note 1). Molecular 
properties include somatic alterations with a predicted damaging effect on the protein 
function (gene gains and losses, translocations, inversions, insertions, truncating and 
non-truncating damaging alterations and gain of function mutations) as well as the 
overall mutation burden and the gene copy number (Supplementary Table 1). 
Systems-level properties are genomic, epigenomic, evolutionary, network and gene 
expression features that distinguish cancer genes from other genes. They include 
gene length and protein domain organisation9,10, gene duplicability11,12, chromatin 
state13, connections and position in the protein-protein interaction network11, number 
of associated regulatory miRNAs12, gene evolutionary origin12 and breadth of gene 
expression in human tissues9,10 (Supplementary Table 1). 
sysSVM is composed of three steps (Figure 1A, Supplementary Note 1). In 
step 1, 34 features describing the gene molecular and systems-level properties are 
mapped to all genes in each patient. In step 2, known cancer genes altered in the 
patient cohort are used to run a set of three-fold cross validations and identify the 
best models in four kernels (linear, sigmoid, radial, polynomial). In step 3, these best 
models are used for training and prediction. All altered genes except the known 
cancer genes used for training are first scored in each patient individually by 
combining the predictions of the four kernels and then ranked according to the 
resulting score. Since the hypothesis is that the strength of the contribution of a gene 
to cancer depends on how similar its properties are to those of known cancer genes, 
the top scoring genes in each patient are the most likely contributors to cancer 
progression. The overall results are combined to obtain the final list of predicted 
cancer genes.  
We applied sysSVM to 261 EACs from OCCAMS, which are part of the ICGC 
dataset (Figure 1B, Supplementary Data 1). In step 1, we extracted 17,078 genes 
with predicted damaging alterations (median of 382 damaged genes per patient) and 
mapped their 34 features. We verified that there is no pairwise correlation between 
these features (Supplementary Figure 1). Moreover, 476 known cancer genes14 
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altered in the 261 EACs (Supplementary Data 2) tend to cluster in distinct regions of 
the feature space (Supplementary Figure 2). This confirms that these features 
distinguish cancer genes from other genes. In step 2, we ran 10,000 iterations of a 
three-fold cross validation using the 476 known cancer genes and combined the 
results to obtain 500 best models for each kernel (Supplementary Table 2, Methods). 
In step 3, we trained the four classifiers with these best models and used them to 
score and rank the remaining 16,602 altered genes in each patient. Since the gene 
score reflects a gradient between driver and passenger activity, we considered the 
top 10 scoring genes in each EAC as the main cancer contributors for that patient. 
We verified that the main findings of our study hold true if we apply higher or lower 
cut offs (see below). Overall, this produced 500 lists of top 10 scoring genes in each 
sample (Supplementary Table 2, Methods). We considered the list of 952 genes that 
occurred most frequently as the final set of predicted cancer genes (Supplementary 
Data 3). Since our hypothesis is that these genes help the known drivers to promote 
cancer, we define them as helper genes.  
We investigated the importance of each feature in the four classifiers by 
ranking the 34 features based on their weight15 and observed interesting properties 
of the four models. Firstly, categorical features were the top contributors for linear 
kernels (linear and polynomial), while both categorical and continuous features 
contributed to non-linear kernels (radial and sigmoid, Supplementary Figure 3). This 
likely reflects intrinsic differences across kernels, supports their integration to capture 
different regions of the feature space and increase the chances of identifying rare 
helpers. Secondly, no feature had zero weight in all four kernels, indicating that all 
features contributed to the final gene classification. Thirdly, despite the high 
prevalence of copy number gains (Supplementary Table 1), gene amplification was 
not the highest-ranking feature in any kernel (Supplementary Figure 3). We next 
checked whether nodes with similar topological properties in the protein-protein 
interaction network had also similar functional properties, since this may bias the 
final classification. A pathway enrichment analysis of the 2,608 central hubs of the 
network resulted in 528 enriched pathways (FDR=0.01), representing 46% of all 
Reactome pathways. This indicates large diversity in the functions of central hubs 
and excludes that nodes with similar topological properties necessarily have similar 
functional properties. Furthermore, a pathway enrichment analysis only considering 
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252 central hubs encoded by known cancer genes resulted in 158 enriched 
pathways (FDR=0.01). Of these, 135 are in common with all central hubs, indicating 
that cancer-related functions constitute a small fraction of pathways enriched in 
central hubs. 
Helper genes localise to the same high-density regions of known cancer genes 
(Figure 1C), with lower scoring genes being further away (Supplementary Figure 3). 
The properties of top scoring genes therefore resemble those of known cancer 
genes. Consistent with the prevalence of gene amplification in EAC (Supplementary 
Table 1), the vast majority of the 952 helpers undergo copy number gain (Figure 1D), 
resulting in their increased expression (Figure 1E). Although prevalent gene 
amplification does not bias the best models (Supplementary Figure 3), we 
investigated its impact on the final predictions. First, only a minority of all amplified 
genes in the 261 EACs are predicted as helper genes (Supplementary Figure 4). 
Second, the 952 final helpers are amplified 6,296 times in the 261 EACs, but they 
are only predicted as helpers 2,062 times (Supplementary Figure 4). Therefore, gene 
amplification alone is not sufficient for a gene to be predicted as a helper. Despite 
the majority of helpers being rare or patient-specific (Figure 1F), some are altered in 
over 10% of EACs (Supplementary Data 3) and are usually associated with 
frequently occurring amplifications16 (Supplementary Figure 4).  
We next assessed the robustness of our predictions. First, we evaluated the 
performance of sysSVM using two independent cohorts, 86 EACs from The Cancer 
Genome Atlas (TCGA) and 21 EACs from another study17 (Supplementary Data 1). 
We scored all altered genes, including known cancer genes14, in each of the 107 
EACs independently, using the four best models trained on the ICGC cohort. In both 
datasets, known cancer genes have significantly higher scores than the rest of the 
altered genes (Supplementary Figure 3), indicating that sysSVM is able to recognise 
them as major cancer contributors. Second, we searched whether any of the 952 
helpers were previously identified as cancer genes. We found that 41 helpers (4%) 
have recently been added to the Cancer Gene Census14 and 171 helpers (18%) 
have been predicted as candidate cancer genes in various cancers, including EAC5 
(Supplementary Data 3). Third, we searched for possible false positive predictions 
using two lists. The first was composed of 49 genes predicted as false positives of 
recurrence-based methods5 and contained only three helpers (PCLO, CNTNAP2 
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and NRXN3; Supplementary Data 3). Interestingly, PCLO has recently been shown 
to exert an oncogenic role in esophageal cancer by interfering with EGFR 
signalling18. The second list was a manually curated set of 488 putative false 
positives3 and contained 44 helpers (4.6% of the total). This is less than the fraction 
of known cancer genes14 present in the same list of false positives (46/719, 6.4%). 
Altogether these analyses indicate that sysSVM robustly predicts cancer genes in 
multiple patient cohorts, with a minimal false positive rate. 
 
Helper genes perturb cancer-related biological processes 
To gather a comprehensive characterisation of the molecular determinants of 
EAC, we analysed the biological processes perturbed by helpers compared to 
drivers. We manually reviewed the 476 known cancer genes14 with damaging 
alterations in the OCCAMS cohort and retained 202 of them based on the 
concordance between the type of acquired modification and literature evidence of 
their role as oncogenes or tumour suppressors (Supplementary Data 2). The median 
number of drivers per EAC is in accordance with recent estimates19 with prevalence 
of gene amplification (Supplementary Figure 4). We then performed two independent 
gene set enrichment analyses, with either 202 known drivers or 952 helpers, to 
dissect their relative functional contribution to EAC. This led to 212 and 189 enriched 
pathways out of the 1,877 tested, respectively (FDR <0.01, Supplementary Data 4, 
Supplementary Figure 4). The analysis of known drivers resulted in a higher number 
of enriched pathways than helpers, despite their lower number. This reflects the 
higher number of pathways that drivers map to (median of four pathways for drivers 
and two pathways for helpers).  
Seventy-three pathways (over 34%) enriched in known drivers are perturbed in 
over 50% of EACs (Supplementary Data 4, Supplementary Figure 5). These 
universal cancer pathways are involved in well-known cancer-related processes, 
including intracellular signalling, cell cycle control, apoptosis and DNA repair, and 
are associated with the most recurrently altered known drivers (TP53, CDKN2A, 
MYC, ERBB2, SMAD4, CDK6, KRAS; Supplementary Data 2). Interestingly, 50 of 
the 73 (70%) are also enriched in helpers and 86 patients with altered helpers in a 
universal cancer pathway have no known drivers in that pathway (Figure 2A, 
Supplementary Data 4). This indicates that helpers often contribute to the 
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perturbation of key cancer pathways and that their alteration may be sufficient for 
cancer development in the absence of known drivers.  
Next, we clustered EACs according to the proportion of shared perturbed 
pathways (Methods, Figure 2B). When using pathways enriched in known drivers, 
we identified five well-supported clusters (1D-5D, Figure 2C, median silhouette 
score=0.5, Supplementary Figure 6). These clusters are clearly driven by the 
mutational status of the most recurrent drivers. For example, TP53 is altered in 
clusters 1D-3D, EGFR, ERBB2 and MYC are altered in cluster 1D and MYC and 
KRAS are altered in cluster 2D (Figure 2D, Supplementary Data 1). Samples in 
clusters 4D and 5D show an overall lower mutational burden (p=0.03, Wilcoxon rank 
sum test), fewer known drivers and consequently a lower number of enriched 
pathways (p=7x10-6, Wilcoxon rank sum test).  
When clustering EACs according to the pathways enriched in helpers, we 
identified six well-supported clusters (1H-6H, Figure 2C, median silhouette 
score=0.3, Supplementary Figure 6). Here, samples are brought together not by the 
recurrent alterations of the same helpers, but by different helpers mapping to the 
same or related pathways (Supplementary Data 1). For example, both clusters 1H 
and 3H show diffuse perturbations in intracellular signalling (Figure 2C), often 
involving universal cancer pathways (Supplementary Data 4, Supplementary Figure 
7). In over 43% of EACs in both clusters, perturbations in universal cancer pathways 
occur in patients with no drivers. Other pathways perturbed in cluster 1H, but not in 
3H, involve cell cycle regulation, Toll-like receptor signalling and proteasome activity 
(Supplementary Data 1, Supplementary Figure 7). EACs in cluster 1H are also 
significantly associated with several known drivers including RECQL4, RARA, MYC, 
SMARCE1 and ERBB2 (Figure 2D), which are often but not always co-altered 
(Supplementary Figure 4). They have a prevalence of mutational signature S3 and 
are enriched in early (stage 2) tumours (Figure 3A). Patients in cluster 3H are 
instead enriched in tobacco smokers (Figure 3A). 
The processes perturbed in clusters 2H and 4H are also functionally related, in 
this case to cell cycle regulation (Figure 2C). All EACs in cluster 2H have helpers 
involved in the regulation of G1/S transition (Supplementary Figure 7), including 
members of the E2F family of transcription factors and associated co-activators, 
competitors and downstream targets (Supplementary Data 1). Cluster 4H instead 
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harbours perturbations in DNA replication, with alterations in the MCM complex, a 
downstream target of E2F20. Dysregulation of E2F transcription factors or the MCM 
complex can induce genomic instability through either aberrant cell-cycle control or 
replicative stress21. Indeed, EACs in clusters 2H accumulate significantly more 
damaged and amplified genes, while those in 4H show significantly more deletions 
and are enriched in mutational signature 2 (Figure 3A). Cluster 2H also shows 
significant alterations of the known drivers GNAS, SS18L1, and FHIT (Figure 2D). 
FHIT is linked to increased genomic instability22 and regulates the expression of cell 
cycle-related genes23, therefore potentially affecting the G1/S transition pathways of 
this cluster. Cluster 4H shows frequent alterations in the known drivers TRAPP and 
CDK6 (Figure 2D). The latter functions in various cell cycle-related pathways, 
including the mitotic G1/S phase pathway altered in 100% of cluster 4H 
(Supplementary Data 1, Supplementary Figure 7). Interestingly, elevated expression 
of the MCM complex has been associated with tumour aggressiveness and poor 
outcome24. Their perturbation could therefore explain the significantly lower survival 
observed for patients in cluster 4H (Figure 3B). Finally, cluster 5H shows 
perturbations in the Toll-like receptor (TLR) signalling cascade (Supplementary 
Figure 7) that has recently been linked to EAC25.  
Overall, clusters 1H to 5H account for 166 EACs (64% of the total cohort). The 
remaining 95 EACs in cluster 6H share fewer perturbed pathways, although 55 of 
them (58%) have alterations in Rho GTPase activity (Supplementary Figure 7) with 
frequent modifications of Rho GTPase effectors including ROCK1, PTK2, PAK1, 
LIMK1 and NDE1 (Supplementary Data 1). EACs in the six clusters obtained using 
helpers are broadly dispersed in the clustering of known drivers (Figure 2C) 
indicating that helpers bring together patients with similar perturbed processes that 
cannot be appreciated when focussing only on recurrent drivers. 
To test whether the germline genetic makeup of EAC patients was associated 
with the somatic perturbation of specific processes, we identified patients with 
potentially damaging germline variants in 152 known cancer predisposition genes26. 
Overall, we found 82 patients with damaging variants in 54 predisposition genes, 
with no significant enrichment compared to European controls27 (Supplementary 
Figure 8). This is expected since the heritable component of EAC is spread over a 
large number of low-impact loci28. We then tested for associations between cancer 
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predisposition genes and clusters of helpers or drivers. The only significant result 
was a depletion of predisposition variants in cluster 4H, which is characterised by 
diffuse perturbations in DNA replication (Figure 3A). Interestingly, the 54 cancer 
predisposition genes damaged in EAC patients are enriched in DNA repair pathways 
(FDR=2.3x10-10, Fisher’s exact test). It is tempting to speculated that germline 
damages affecting DNA repair pathways would render additional somatic 
perturbations in the same pathways lethal and therefore be counter-selected.  
Finally, we checked whether patient clustering is affected by the number of 
helper genes considered in each patient. We performed the same analysis 
considering the top five or top 15 scoring genes (528 and 1,297 unique genes, 
respectively). We found that the vast majority (99% and 77%) of the pathways 
enriched in these datasets are also enriched when considering the top 10 helpers 
(Supplementary Figure 8), indicating that the recurrently perturbed processes are 
highly overlapping. We then clustered EACs according to the proportion of shared 
perturbed pathways and verified that the six clusters obtained using pathways 
enriched in top 10 genes recapitulated well the clusters obtained using top five or 15 
genes (Supplementary Figure 8). Therefore, the clustering is robust regardless of the 
applied ranking cut-off.  
 
Helper alterations lead to cancer phenotypes and dependence 
To test the contribution of EAC helper genes to cancer, we used two 
experimental approaches. In the first approach, we assessed the consequences of 
altering (1) frequently or rarely altered helpers; (2) loss of function alterations or of 
function/overexpression; and (3) processes that define specific helper clusters or that 
are altered across all helper clusters. We used diploid EAC FLO-1 cells that have no 
alterations in any of the helpers selected for validation14 to allow a clear evaluation of 
the effect of their induced alteration. We measured cell proliferation as a main 
hallmark of cancer3 and also performed gene-specific assays. In the second 
approach, we evaluated the dependence of EAC on helper perturbations by 
assessing the effect of reverting their alterations on cell growth. For this, we used 
EAC cell lines with alterations similar to those observed in patients.  
First, we modified the most commonly altered helpers in clusters 2H and 4H, 
E2F1 (23 out of 24 samples in cluster 2H) and MCM7 (18 out of 37 samples in 
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cluster 4H, Supplementary Data 1). Both E2F1 and MCM7 are amplified in EACs 
(Supplementary Data 3) leading to significant gene overexpression (median two-fold 
increase, p=6x10-3 and p=8x10-3, respectively, Wilcoxon rank-sum test; Figure 4A). 
We therefore overexpressed E2F1 and MCM7 in FLO-1 cells to levels comparable to 
those observed in patients (Figure 4B). In both cases, this resulted in significantly 
increased proliferation of overexpressing cells compared to control cells (p=2x10-4 
and p=9x10-4, respectively, two-tailed t-test; Figure 4C). Since E2F1 promotes cell 
cycle progression, we assessed DNA replication rate by EdU incorporation. We 
observed increased EdU intensity throughout S phase in E2F1 overexpressing cells 
compared to control cells (p<10-4, Mann Whiney U test; Figure 4D). This suggests 
that E2F1 may help cancer growth by promoting S phase entry. To assess the 
consequence of MCM7 overexpression, we measured the loading of the MCM 
complex onto chromatin. MCM7 overexpressing cells display a lower MCM 
fluorescence intensity overall compared to control cells when staining the chromatin-
bound fraction for either MCM7 or MCM3 (p<10-4, Mann-Whitney U test; Figure 4E, 
4F). This suggests that less MCM complex is loaded onto chromatin by the start of S 
phase. Therefore, MCM7 overexpression leads to both increased proliferation and 
perturbation of MCM complex activity. Finally, we reduced MCM7 expression levels 
in MFD-1 cells derived from one of our EAC patients29. MFD-1 cells have four-fold 
higher MCM7 basal expression compared to FLO-1 cells (Figure 4G). We therefore 
used a doxycycline-inducible shRNA lentiviral vector (Supplementary Table 3) to 
reduce MCM7 expression in MFD-1 cells to the level of FLO-1 cells (Figure 4H). This 
led to a significant decrease in proliferation (p=2x10-5, two-tailed t-test; Figure 4I), 
indicating that MFD-1 cells rely on MCM7 overexpression for their growth. 
Next, we evaluated the role of rarely altered helpers, such as NCOR2 that is 
altered in eight EACs across five of the six clusters (Supplementary Data 3). NCOR2 
contributes to the nuclear receptor corepressor complex that favours global 
chromatin deacetylation and transcriptional repression5,30 (Figure 5A). Consistently 
with the suggested tumour suppressor role of NCOR2 in lymphoma and prostate 
cancer31, the most frequent NCOR2 alterations in EAC lead to a loss of function. To 
reproduce these alterations, we edited NCOR2 in FLO-1 cells using a vector-free 
CRISPR system32 (Methods, Supplementary Table 3) and the editing was quantified 
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using MiSeq (Figure 5B). We observed a 1.3-fold increase in proliferation of edited 
cells compared to the control cells (p=3x10-3, two-tailed t-test test; Figure 5C). 
Then, we tested the effect of altering members of the Rho GTPase effector 
pathway, pervasively perturbed in all six clusters, often through patient-specific 
alterations (Figure 5D, Supplementary Data 1). We modified ABI2 and PAK1, which 
undergo damaging alterations and amplification in one and nine EACs, respectively 
(Supplementary Data 3). We therefore edited ABI2 and overexpressed PAK1 as 
described above (Supplementary Table 3, Figure 5E) and observed significantly 
increased proliferation compared to control cells (ABI2: p=4x10-4, PAK1: p=1x10-3 
two-tailed t-test; Figure 5F).  
Finally, we focussed on PSMD3 encoding a subunit of the regulatory 19S 
proteasome complex. PSMD3 is amplified and overexpressed in three EACs of 
cluster 1H, which overall contains 14 samples with alterations in six proteasome 
subunits (Figure 6A and Supplementary Data 3). Three EAC cell lines (MFD-1, OE19 
and OE33) show higher basal expression of PSMD3 compared to FLO-1 (2-, 3- and 
4-fold increase respectively, Figure 6B). Using a doxycycline-inducible lentiviral 
shRNA vector (Supplementary Table 3), we reduced PSMD3 expression in MFD-1, 
OE19 and OE33 cells to levels equivalent to those of FLO-1 (Figure 6C). In all three 
cell lines we observed a significant reduction in cell proliferation following the 
reduction of PSMD3 expression (MFD-1: p=4x10-8; OE19: p=2x10-8; OE33: p=6x10-3, 
two-tailed t-test; Figure 6D). The effect was particularly strong in OE19, where cell 
growth was arrested completely. MFD-1 and OE33 showed 1.3- and 1.2-fold 
reductions in cell growth (Figure 6D). This suggests that the extent of EAC reliance 
upon helper alterations is at least partially context dependent. 
Taken together, our experimental data indicate that, independently of the 
alteration frequency, the modification of helpers positively affects EAC cell growth. 
The fold changes in proliferation rate observed upon perturbation of helpers are in 
the same range as those observed following alteration of known strong drivers 
including TP53 or PIK3CA33,34. Moreover, we provide evidence that EAC cells 
become addicted to helper alterations, suggesting that targeting helpers, or the 
pathways in which they act, could reduce EAC progression. 
 
Helper alterations promote growth in Barrett’s esophagus 
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To evaluate the role of helper perturbations in the early stages of EAC, we 
quantified their alterations in 82 samples of Barrett’s esophagus (BE)35, a pre-
malignant condition associated with EAC. When considering both damaging and 
non-damaging alterations, the percentages of helpers and known drivers14 altered in 
the whole BE cohort were comparable to that of cancer-unrelated genes (Figure 7A). 
However, when considering only damaging alterations, helpers showed significant 
enrichment compared to the rest of genes (p=4x10-13 and p=3x10-6, respectively, 
Fisher’s exact test; Figure 7B). Early alteration of helpers in pre-malignant lesions 
suggests that they may favour the transition to cancer. To further validate this 
hypothesis, we altered representative helpers in BE CP-A cells and evaluated the 
impact of their alterations on cell growth. As already reported6,35, damaging point 
mutations were the most common alterations in BE (Figure 7C). Therefore, we 
edited ABI2 and NCOR2 to mimic their putative loss-of-function alterations. Since 
CP-A cells have wild-type TP5336, we also edited TP53 to compare the effect of 
altering helpers to that of altering a strong driver. After confirming high editing levels 
(Figure 7D), we observed a significant increase in cell proliferation compared to 
control cells in all three cases (ABI2: p=3x10-4, NCOR2: p=1x10-2, TP53: p=1x10-4, 
two-tailed t-test; Figure 7E). Strikingly, both helpers promote cell growth to 
comparable levels of TP53, suggesting that helper alterations can favour early 
cancer progression to a similar extent to driver alterations.  
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DISCUSSION 
Most state-of-the-art approaches to discovering cancer driver events rely on the 
detection of positively selected alterations of genes that promote cancer 
development3,19. Even ratiometric methods based on gene properties37 ultimately 
assess the effect of positive selection and distinguish the few selected drivers from 
the many passenger events. As a result, the discovery of cancer drivers is biased 
towards frequently altered genes, with significant limitations for cancers such as EAC 
that have a highly variable but mostly flat (i.e. with few recurrent events) mutational 
landscape. Indeed, the overall selection acting on esophageal cancer genomes is 
among the lowest across cancer types19, despite a median of 382 damaged genes 
per EAC (Supplementary Data 1). Therefore, the exclusive focus on genes under 
strong selection is likely to return only a partial representation of the genes involved 
in EAC.  
To overcome these limitations, our machine learning approach sysSVM ranks 
somatically altered genes relevant to cancer development based on their properties 
rather than mutation recurrence. sysSVM also considers all types of gene alterations 
(SNVs, indels, CNVs, and structural variations) simultaneously, providing a 
comprehensive overview of the genetic modifications with a cancer role in individual 
patients. When applied to 261 EACs, sysSVM prioritises 952 altered genes that, 
together with known drivers, help cancer progression. The large number reflects the 
positive correlation between mutational burden and number of driver genes, which is 
only partially explained by a sample size effect3. This positive correlation may 
indicate that the number of functionally relevant genes increases with the number of 
altered genes. 
The heterogeneous landscape of EAC is substantially reduced by considering 
the perturbed biological processes (Figure 2C). Most of these processes are well-
known contributors to cancer development, including intracellular signalling, cell 
cycle control, and DNA repair (Supplementary Data 4). Interestingly, while the known 
drivers tend to encode upstream players in these pathways, helpers are often 
downstream effectors. For example, we found several Rho GTPase effectors (Figure 
5D, Supplementary Data 3) or genes downstream of previously reported EAC drivers 
in the Toll-like receptor cascade (Supplementary Data 3). This supports a more local 
role of helpers in contributing to cancer at the single patient level, through sustaining 
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or complementing driver functions. In this respect, helpers are conceptually similar to 
mini-drivers38. 
Clustering pathways disrupted by helpers allows the division of the 261 EACs 
into six functional clusters that are often functionally related. For example, clusters 
1H and 3H share perturbations in intracellular signalling. Similarly, clusters 2H and 
4H show perturbations in cell cycle regulation, including S-phase entry and DNA 
replication. Consistent with this, they bring together the most genomically unstable 
samples. By experimentally mimicking the amplification of E2F1 (representative of 
cluster 2H) and MCM7 (representative of cluster 4H), we increased proliferation in 
EAC cells (Figure 4C). We also provide evidence that E2F1 increases proliferation 
by promoting S phase entry (Figure 4D). Interestingly, MCM7 overexpression 
reduced MCM complex loading onto chromatin (Figure 4E and 4F), maybe due to a 
stoichiometric imbalance of complex subunits. This may indicate that MCM7 
promotes cell growth through a separate mechanism besides its function in the MCM 
complex. For example, MCM7 interacts with the tumour suppressor protein Rb, a 
well-characterised inhibitor of E2F139. It is possible that MCM7 overexpression may 
sequester Rb away from E2F1, thereby promoting E2F1-mediated cell cycle 
progression. Moreover, reducing MCM7 expression in cells with high basal 
expression led to decreased cell proliferation, showing the dependence of cancer 
cells on this alteration. 
We also confirmed the cancer promoting role of very rare helpers, including 
ABI2, NCOR2 and PAK1 that are altered in 1-4% of EACs (Figure 5C and 5F). 
Therefore, irrespective of the frequency across patients, helpers have a substantial 
impact on cancer progression. We therefore speculate that it is the contribution of 
several genes perturbing the same pathways that promotes cancer progression 
rather than the alteration of one gene alone. In line with this, the dysregulation of a 
strong driver including TP5333 or PIK3CA34 alone does not have a dramatic effect. 
This is confirmed by our data where the alteration of one helper gene has a mild yet 
significant effect on cell proliferation. Interestingly, helpers are also frequently altered 
in pre-cancerous lesions known as Barrett’s esophagus (Figure 7B), indicating that 
their alteration may be an early event in EAC transformation. Consistent with this, 
the perturbation of helpers leads to increased proliferation in BE cells and the effect 
is comparable to that of perturbing TP53 (Figure 7E). 
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The expansion of the repertoire of cancer genes may indicate new, patient-
specific gene dependencies suggesting possible stratifications that could inform the 
selection of targeted treatments. For example, 14 samples of cluster 1H have 
alterations of several proteasome subunits (Figure 6A, Supplementary Data 1). 
Experimentally reverting the expression of the proteasome subunit PSMD3 to diploid 
levels reduced proliferation in three different EAC cell lines (Figure 6D), suggesting 
that EACs become addicted to helper alteration and vulnerable to its inhibitions. 
Interestingly, proteasome inhibition has been shown to have a synergic effect in 
combination with ERBB2 inhibitors40. Since ERBB2 is also significantly altered in 
cluster 1H (Figure 2D), a combined therapy may be beneficial to patients in this 
cluster. 
In summary, we provide an attempt to extend the discovery of acquired 
perturbations contributing to cancer beyond those of recurrent drivers. Additional 
efforts are required to fully exploit the potential of these approaches to offer a more 
comprehensive view of the molecular mechanisms behind cancer and to guide 
clinical interventions. 
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METHODS 
Annotation of molecular properties 
Data on somatic single nucleotide variations (SNVs), small insertions and deletions 
(indels), copy number variations (CNVs), structural variations (SVs), and mutational 
signatures for 261 EACs were obtained from ICGC and analysed as previously 
described16 (Supplementary Data 1). Briefly, SNVs and indels were called using 
Strelka v.1.0.1341 and subsequently filtered 16. For CNVs, the absolute copy number 
for each genomic region was obtained from ASCAT-NGS v.2.142 after correction for 
tumour content, using read counts at germline heterozygous positions as derived 
from GATK v.3.2-243. To account for the high number of amplifications occurring in 
EAC, copy number gains were corrected by the ploidy of each sample as estimated 
by ASCAT-NGS. A gene was assigned with the copy number of a CNV region if at 
least 25% of its length was contained in that region. SVs (gene translocations, 
inversions, insertions) were identified from discordant read pairs using Manta44 after 
excluding SVs that were also present in more than two normal samples of a panel of 
15 esophagus and 50 blood samples16. In the case of TCGA validation cohort, 
SNVs, indels, and CNVs were derived from level 3 TCGA annotation data of 86 
EACs (Supplementary Data 1). In the case of 21 EACs from a previous study17, 
SNVs, indels, and CNVs were called as described for the ICGC samples 
(Supplementary Data 1). The distribution of variant allele frequency of SNVs and 
indels across all samples was used to remove outliers likely indicating sequencing or 
calling artefacts. Variants with <10% frequency and indels longer than five base 
pairs were also removed. For CNVs, genomic regions were considered as amplified 
or deleted if their segment mean was higher than 0.3 or lower than -0.3, respectively, 
capping the segment mean to 1.5 to avoid hypersegmentation45. A gene was 
considered as amplified or deleted if at least 25% of its length was contained in a 
CNV region and the resulting copy number (CN) was estimated as: 
CN = 2 × 2𝑠𝑒𝑔𝑚𝑒𝑛𝑡 𝑚𝑒𝑎𝑛 (1) 
No SV data were available for the validation cohorts.  
Since only genes with predicted damaging alterations were used as input for 
sysSVM, further annotation for the variant damaging effect was performed. Stopgain, 
stoploss, frameshift, nonframeshift, nonsynonymous, and splicing SNVs and indels 
were annotated using ANNOVAR (December 2015)46. All truncating alterations 
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(stopgain, stoploss, and frameshift mutations) were considered as damaging. 
Nonframeshift and nonsynonymous mutations were considered as non-truncating 
damaging alterations if predicted by at least five of seven function-based methods 
(SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, MutationTaster, MutationAssessor, 
LRTand FATHMM) or by two out of three conservation-based methods (PhyloP, 
GERP++ RS, SiPhy), using the scores from dbNSFP v.3.047. Splicing modifications 
were considered as damaging if predicted by at least one of the two ensemble 
algorithms as implemented in dbNSFP v3.0. Putative gain of function alterations 
were predicted with OncodriveClust48 with default parameters and applying a false 
discovery rate of 10%. The transcript lengths to estimate mutation clustering were 
derived from the refGene table of UCSC Table Browser 
(https://genome.ucsc.edu/cgi-bin/hgTables). Gene gains, homozygous losses, 
translocations, inversions, insertions were always considered as putative damaging 
alterations. 
Overall, 17,078 genes had at least one damaging alteration, for a total of 116,989 
redundant damaged genes across 261 EACs (Supplementary Table 1). Of these, 
476 were known cancer genes14, corresponding to 4,091 redundant genes 
(Supplementary Data 1). For all 17,078 genes, the total number of exonic alterations 
(silent and nonsilent) and the somatic copy number were used as additional 
molecular features in sysSVM. 
 
Annotation of systems-level properties 
Protein sequences from RefSeq v.6349 were aligned to the human reference genome 
assembly GRCh37 to define unique gene loci 10. The length of the longest coding 
sequence was taken as the gene length. Genes aligning to more than one gene 
locus for at least 60% of the protein length were considered as duplicated genes11. 
Data on human ohnologs (gene duplicates retained after whole genome 
duplications) were collected from Makino et al., 201350. The number of protein 
domains was derived from CDD51. The gene chromatin state based on Hi-C 
experiments13 was retrieved from the covariate matrix of MutSigCV v1.2.012. Data on 
protein-protein and miRNA-gene interactions, gene evolutionary origin and gene 
expression were retrieved as described in An et al., 201610. Briefly, human protein-
protein interaction network was rebuilt from the integration of BioGRID v.3.4.12552; 
MIntAct v.19053; DIP (April 2015)54; HPRD v.955; the miRNA-gene interactions were 
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derived from miRTarBase v.4.556 and miRecords (April 2013)57; gene evolutionary 
origin was assessed as described in D’Antonio et al., 201112 using gene orthology 
from EggNOG v.458; and gene expression in 30 normal tissues was retrieved from 
GTEx v.1.1.859. Except gene length, duplication and ohnologs, all other systems-
level properties had missing information for some of the 17,078 altered genes 
(Supplementary Table 1). To account for this, median imputation for continuous 
properties and mode imputation for categorical properties were implemented. 
Specifically, for each property median or mode values were calculated for known 
cancer genes and the rest of mutated genes. All missing values were replaced with 
their corresponding median or mode values. 
 
Application of sysSVM to EACs 
The three steps of sysSVM were applied to 261 EACs (Figure 1A, Figure 1B, 
Supplementary Note 1). In step 1, all 34 features derived from molecular and 
systems-level properties (Supplementary Table 1) were mapped to the 17,078 
altered genes in the cohort. Each feature was scaled to zero mean and unit variance 
to correct for the different numerical ranges across them. In step 2, 476 known 
cancer genes with damaging alterations (Supplementary Data 2) were used as a set 
of true positives for model selection. To optimise the parameters of the four kernels 
(linear, radial, sigmoid and polynomial) a grid search using 10,000 iterations of a 
three-fold cross validation was performed. At each iteration, the 476 known cancer 
genes were randomly split into 2/3 (around 317 genes) used as a training set and 1/3 
(around 159 genes) used as the test set. At each increment of 100 cross validation 
iterations, the four best models (one per kernel) were chosen based on the median 
and variance of the sensitivity distribution across all previous iterations of cross-
validation. The selection of the 100 sets of best models from all 10,000 cross-
validation iterations was repeated 5 times, where all iterations were randomly re-
ordered. In step 3, the resulting 500 best models were trained with the whole training 
set and used to rank the remaining 16,602 unique genes in each patient. A score 
was measured to combine the predictions from the four kernels and the genes not 
expressed in normal esophagus according GTEx annotation were excluded. These 
produced 500 lists of top 10 genes. Out of 500 best models, 38 had a unique set of 
parameters resulting in 24 unique lists of top 10 genes (Supplementary Table 2). 
These 24 lists ranged between 898 and 952 genes, with a core set of 598 genes 
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shared across all of them. The most frequent top 10 list occurred 207 times (952_A, 
41.4%, Supplementary Table 2). It was followed by 952_B (32.2%, 161 times) and 
951_A (8.6%, 43 times). These three lists accounted for 82.2% of the 500 sets of top 
10 genes, they shared 950 genes and were predicted by models differing in only one 
parameter (gamma in the polynomial kernel, Supplementary Table 2). Furthermore, 
the most frequent list was always predicted by the same set of best models. 
Therefore, 952_A represented a robust set of prediction and was considered as the 
final list of helper genes (Supplementary Data 3). To quantify the relative contribution 
of the 34 features to the four best models used to predict the final set of helper 
genes in the 952_A final list. Recursive Feature Elimination (RFE)15 was 
implemented. RFE first defines the best set of parameters for each kernel. Secondly, 
RFE trains the one-class classifier in each kernel and computes the weight (w) of 
each feature, defined as the product of the sysSVM coefficients with each support 
vector. Thirdly, RFE ranks the features according to w2 and recursively removes the 
feature with the smallest value of w2 until no feature remains. In the case of sysSVM 
this was done 34 times until all sysSVM features were ranked (Supplementary 
Figure 3). 
 
Identification of perturbed processes and patient clustering 
To identify the perturbed biological processes in the EAC cohort, both predicted 
cancer helper genes and known cancer genes were used. A manual revision of 476 
known cancer genes altered in the ICGC cohort was performed and genes were 
considered as known drivers if (a) their somatic alteration had been previously 
associated with EAC, (b) they had a loss-of-function alteration and their tumour 
suppressor role had been reported in other cancer types60, (c) they had a gain-of-
function alteration and their oncogenic role had been reported in other cancer 
types60. The resulting 202 known cancer drivers (Supplementary Data 2) and 952 
cancer helpers were used for the gene set enrichment analysis against Reactome 
v.5861, composed of 1,877 pathways and 10,131 genes. After excluding pathways in 
levels 1 and 2 of Reactome hierarchy and those with less than 10 or over 500 genes, 
1,155 pathways were retained. These contained 9,061 genes, including 155 known 
drivers and 648 helpers. Gene set enrichment was assessed using a one-sided 
hypergeometric test and the resulting P values were corrected for multiple testing 
using the Benjamini & Hochberg method (Supplementary Data 4). Enriched 
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pathways within the sets of known drivers or helpers were subsequently used to 
cluster samples taking into account the proportion of perturbed processes shared 
between samples. The Jaccard index (A) was calculated by deriving the proportion 
of shared perturbed processes between all possible sample pairs as: 
𝐴𝑖𝑗 = |𝑃𝑖 ∩ 𝑃𝑗| ∕ |𝑃𝑖 ∪ 𝑃𝑗| (2) 
 
where Pi and Pj are the perturbed processes in samples i and j, respectively.  
Complete linkage hierarchical clustering using Euclidean distance between each row 
was performed on the resulting matrix. Clusters were visualised using 
ComplexHeatmap R package62. To identify the optimal number of clusters, the 
median silhouette value of the samples for between 3 and 20 clusters was measured 
as a measure of clustering robustness63. 
 
Annotation of germline variants 
Starting from germline variants (SNVs and indels)16, a series of filters were applied. 
First, heterozygous calls with Variant Allele Frequency (VAF) deviating from 50% by 
more than 2.6 standard deviations and homozygous calls with VAF less than 95% 
were removed. Second, variants were removed if their Minor Allele Frequency (MAF) 
in EACs was >10% and substantially larger than in ExAC64 and in the European 
cohort from 1000 Genomes27 using the following formula: 
𝑀𝐴𝐹𝐸𝐴𝐶 > √10 × 𝑀𝐴𝐹𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (3) 
were MAFreference was the MAF in ExAC or 1000 Genomes. 
Finally, variants were also removed if they exhibited an excess of heterozygosity 
determined as: 
𝑝𝐴𝑎 > 1.04 − √1.04 − 3.74 × 𝑝𝐴 × 𝑝𝑎 (4) 
where pAa, pA and pa are the proportion of heterozygote variants, the major allele 
frequency and the minor allele frequency respectively. This formula was empirically 
chosen based on the principle of Hardy-Weinberg equilibrium65. The resulting 
variants were considered damaging if they were frameshift indels, introduced 
stopgains or stoplosses, or if defined damaging in at least five out of seven functional 
predictors as described above. Only rare damaging variants (MAF< 1% in ExAC64 
and in the Europeans from 1000 Genomes27) were further retained. A list of 152 
cancer predisposition genes was obtained from the literature26. EAC patients that 
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carried a rare damaging germline variant in one of these genes were considered to 
carry a cancer predisposition variant. 
 
Analysis of RNA sequencing data 
Purified total RNA was extracted from 92 EACs from the ICGC cohort and 
sequenced 16. RNA sequencing reads were then aligned to human reference 
genome hg19 and expression values were calculated using Gencode v19. The 
summariseOverlaps function in the R GenomicAlignments package was used to 
count any fragments overlapping with exons (parameters mode=Union, singleEnd, 
invertStrand and inter.feature were set according to the library protocol, 
fragments=TRUE, ignore.strand=FALSE). Gene length was derived as the number 
of base pairs in the exons after concatenating the exons per gene in non-overlapping 
regions. FPKM (Fragments Per Kilobase Million) were calculated for each gene as: 
 
𝐹𝑃𝐾𝑀 =  
𝑔𝑒𝑛𝑒 𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡
(𝑙𝑖𝑏𝑟𝑎𝑟𝑦 𝑠𝑖𝑧𝑒/1000000)×(𝑔𝑒𝑛𝑒 𝑙𝑒𝑛𝑔𝑡ℎ/1000)
 (5) 
 
Cell lines 
Overexpression and editing experiments were carried out using the FLO-1 
esophageal adenocarcinoma cell line obtained from the ECACC General Cell 
Collection and CP-A (KR-42421) Barrett’s Esophagus cells from ATCC (catalogue 
number CRL-4027). FLO-1 cells were grown at 37°C and five per cent CO2 in DMEM 
+ 2mM Glutamine + 10% FBS (Biosera) + 1/10,000 units of penicillin–streptomycin. 
CP-A cells were grown at 37°C and five per cent CO2 in Keratinocyte serum-free 
medium with 50µg ml-1 bovine pituitary extract and 5ng ml-1 recombinant human 
EGF (17005042, Thermo Fisher). For passaging of CP-A cells, 250mg L-1 soybean 
trypsin inhibitor in PBS was used (17075029, Thermo Fisher). Gene knockdown 
experiments were performed on OE19 cells obtained from the Francis Crick Institute 
cell services, OE33 cells obtained from the ECACC General Cell Collection and 
MFD1 cells obtained from the OCCAMS Consortium. OE19 and OE33 cells were 
grown in RPMI + 2mM Glutamine + 10% FBS (Biosera) + 1/10,000 units of 
penicillin–streptomycin. MFD1 cells were grown in DMEM + 2mM Glutamine + 10% 
FBS (Biosera) + 1/10,000 units of penicillin–streptomycin. All cells were maintained 
 24 
at 37°C and five per cent CO2, validated by short tandem repeat analysis and 
routinely checked for mycoplasma contamination. 
 
Gene overexpression 
The vectors pCMVHA E2F166 (Item ID 24225, Addgene), pLX_TRC317 
(TRCN0000481188, Sigma-Aldrich) and pcDNA3.1+/C-(K)-DYK (Clone ID: 
OHu19407D, Genscript) were used to induce E2F1, MCM7, and PAK1 
overexpression, respectively. FLO-1 cells were transfected according to the 
manufacturer’s protocol, while CP-A cells were nucleofected following the Neon™ kit 
protocol (Thermo Fisher), with 2 pulses of 1200V for 20ms. Overexpressing cells 
were selected with either G481/Geneticin (E2F1, PAK1) or Puromycin (MCM7). 
Empty vectors carrying G418 (pcDNA3.1+/C-(K)-DYK, Genscript) or Puromycin 
(Item ID 85966, Addgene) resistance were used as controls. The RNA from 
transfected cells was used to assess gene overexpression via quantitative RT-PCR 
using predesigned SYBR green primers (Sigma-Aldrich; Supplementary Table 3) 
and Brilliant III Ultra-Fast SYBR Green QRT-PCR Master Mix (Agilent Technologies). 
The average expression level across triplicates (e) was relativised to the average 
expression level of β-2-microglobulin (c): 
 
𝑟 = 𝑒 − 𝑐 (6) 
where r is the relative gene expression. The fold change (fc) between the relative 
gene expression after overexpression and the relative gene expression in the control 
condition (rc) was calculated as: 
𝑓𝑐 =  2( 𝑟𝑐− 𝑟𝐾𝐷) (7) 
Each sample was assessed in triplicate and each experiment was repeated in 
biological duplicate. 
 
Gene editing 
To induce ABI2 and NCOR2 gene knock-out (KO) in FLO-1 cells, the vector-free 
CRISPR-mediated editing approach was used as previously described32. Briefly, 
cells were co-transfected using lipofectamine CRISPR max (Life technologies) with a 
69-mer tracrRNA (Sigma-Aldrich), three gene-specific crRNAs (Sigma-Aldrich, 
Supplementary Table 3) and GeneArt Platinum Cas9 nuclease (Life technologies). 
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To avoid off-target editing, all crRNAs used were verified to map only the gene of 
interest with a perfect match and additional hits in the genome with at least three 
mismatches. Control cells were transfected with the same protocol but using three 
non-targeting crRNAs. In CP-A cells, vector-free CRISPR-mediated editing of ABI2, 
NCOR2 or TP53 was performed by introducing two gene-specific crRNAs (Synthego, 
Supplementary Table 3) and GeneArt Platinum Cas9 nuclease (Life technologies) 
into the cells by nucleofection following the Neon™ kit protocol (Thermo Fisher), with 
2 pulses of 1200V for 20ms. In all cases, gene editing was confirmed with Illumina 
MiSeq sequencing. The regions surrounding the targeted sites were amplified from 
genomic DNA of edited cells with primers containing Illumina adapters 
(Supplementary Table 3) using Q5 Hot Start High-Fidelity 2X Master Mix (New 
England Biolabs). DNA barcodes were added with a PCR reaction before pooling the 
samples for sequencing on Illumina MiSeq with the 250 base-pair paired-end 
protocol. Sequencing reads were merged into single reads and aligned to the human 
reference genome hg19 using BBMerge and BBMap functions of BBTools67, 
obtaining an average of 78,864 aligned reads per experiment. SNVs and small indels 
in the regions corresponding to each crRNA (Supplementary Table 3) were called 
using the CrispRVariants package in R68 and the percentage of edited alleles was 
estimated as the percentage of variant reads in each experiment. 
 
Gene knockdown 
Inducible gene knockdown was carried out using lentiviral pTRIPZ-TurboRFP 
(MCM7) or pSMART-TurboGFP (PSMD3) shRNA vectors (Dharmacon). For each 
gene, three shRNA vectors were tested (Supplementary Table 3). Virus was 
produced by co-transfecting HEK293T cells with pTRIPZ or pSMART constructs 
alongside psPAX2 and pMD2.G vectors (Addgene) using Fugene HD (Promega). 
Viral supernatant was collected at 24 and 48 hours and used for two rounds of 
infection of OE19, OE33 or MFD1 cells, using 8μg ml-1 hexadimethrine bromide 
(Sigma-Aldrich). Infected cells were selected after 48 hours with 2μg ml-1 puromycin 
for 7 days. To induce shRNA expression, cells were treated with 1μg ml-1 
doxycycline (Sigma-Aldrich) for 16 hours. Gene expression with or without 
doxycycline was assessed by qRT-PCR using predesigned SYBR green primers 
(Sigma-Aldrich; Supplementary Table 3). Cells with the highest level of knockdown 
were then sorted by FACS to isolate medium expressing cells (the middle 30% of 
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cells based on TurboRFP or TurboGFP fluorescence). Gene expression after sorting 
was measured by qRT-PCR 24 hours post-induction with 0-1μg ml-1 doxycycline, to 
determine the concentration of doxycycline required to reduce expression to levels 
equivalent to FLO-1 cells. The determined concentrations of doxycycline used for 
proliferation assays were 0.05μg ml-1 for OE19 PSMD3 shRNA3, 0.25μg ml-1 for 
OE33 PSMD3 shRNA3, 0.25μg ml-1 for MFD1 PSMD3 shRNA3, 0.75μg ml-1 for 
MFD1 MCM7 shRNA3. 
 
Cell proliferation 
Cell proliferation was measured every 24 hours for three or four days, starting three 
hours after seeding the cells (time zero) using crystal violet staining, CellTiter 96 
Non-Radioactive Cell Proliferation Assay (Promega) or CellTiter-Glo Luminescent 
Cell Viability Assay (Promega). Briefly, 4.5x103 cells per well were seeded on 96-well 
plates in a final volume of 100μl per well. For inducible shRNA-expressing cells, 
doxycycline was added 48 hours prior to the start of the assay, and culture media 
replaced every 24-48 hours with fresh media containing doxycycline. For the 
CellTiter 96 Non-Radioactive Cell Proliferation Assay, 15 μl of the dye solution was 
added into each well and cells were incubated at 37°C for two hours. The converted 
dye was released from the cells using 100μl of the solubilisation/Stop solution and 
absorbance was measured at 570nm after one hour using the Paradigm detection 
platform (Beckman Coulter). For the CellTiter-Glo Luminescent Cell Viability Assay, 
100μl of the CellTiter-Glo reagent was added into each well and luminescence was 
measured after 30 minutes using the Paradigm detection platform (Beckman 
Coulter). For all proliferation assays, four replicates per condition were measured at 
each time point and each measure was normalised to the average time zero 
measure for each condition. Each experiment was repeated at least twice. 
Conditions were compared using the two-tailed Student’s t-test. 
 
Flow cytometry 
EdU incorporation and MCM loading were assessed using a modified version of the 
protocol described in Galanos et al., 201669. Briefly, in each condition, 3x106 cells 
were pulsed for 30 minutes with 10µM EdU (Invitrogen) before washing in 1% 
BSA/PBS. Chromatin fractionation was performed by incubating on ice for 10 
minutes in CSK buffer (10mM HEPES, 100mM NaCl, 3mM MgCl2, 1mM EGTA, 
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300mM sucrose, 1% BSA, 0.2% Triton-X100, 1mM DTT, cOmplete EDTA-free 
protease inhibitor cocktail tablets, Roche). Cells were then fixed in 4% 
formaldehyde/PBS for 10 minutes at room temperature before washing in 1% 
BSA/PBS. Cells were permeabilised and barcoded70 by incubating in 70% ethanol 
containing 0-15µg ml-1 Alexa Fluor 488 (Thermo Fisher) for 15 minutes, then washed 
twice in 1% BSA/PBS. Barcoded cells were subsequently pooled before incubating 
in primary antibody (mouse monoclonal anti-MCM7: Santa Cruz Biotechnology sc-
56324, or rabbit polyclonal anti-MCM3: Bethyl Laboratories A300-192A) diluted 
1:100 in 1% BSA/PBS for 1 hour. After washing in 1% BSA/PBS, samples were 
incubated for 30 minutes in secondary antibody (Alexa Fluor 555-conjugated donkey 
anti-mouse: A-31570, or donkey anti-rabbit: A-31572) diluted 1:500 in 1% BSA/PBS, 
then washed again in 1% BSA/PBS. EdU labelling with Alexa Fluor 647 azide was 
performed using Click-iT EdU flow cytometry assay kit (Invitrogen, C10424) following 
the manufacturer’s instructions before washing samples in 1% BSA/PBS. Samples 
were then incubated in 1% BSA/PBS containing RNase and 10mg ml-1 DAPI for 15 
minutes before analysing with a BD LSR II Fortessa flow cytometer (BD 
Biosciences). Lasers and filters used include: 407nm laser with 450/50 bandpass 
filter; 488nm laser with 505 longpass and 530/30 bandpass filters; 561nm laser with 
570 longpass and 590/30 bandpass filters; 640nm laser with 670/14 bandpass filter. 
Compensation was performed manually with single colour controls, using BD 
FACSDiva software (BD Biosciences). FlowJo 10.3 software was used to analyse 
MCM loading onto chromatin and EdU incorporation. Cells were gated to remove 
debris using FSC-A/SSC-A, then gated to isolate singlets using DAPI-H/DAPI-A 
(Supplementary Figure 9). The cells were then separated by gating the barcoded 
populations using 488-A/DAPI-A. Cells were finally separated into cell cycle gates 
(G1, S1-4, G2) based on EdU-647-A and DAPI-A (Supplementary Figure 9), and the 
geometric mean fluorescence intensity was obtained for each channel (MCM-555 or 
EdU-647). 
 
ETHICS 
All subjects gave informed consent, and this study was registered (UKCRNID 8880) 
and approved by the Institutional Ethics Committees (REC 07/H0305/52 and 
10/H0305/1). 
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DATA AVAILABILITY 
WGS and RNA sequencing data can be accessed at the European Genome-
phenome Archive using the accession numbers EGAD00001004775 
[https://www.ebi.ac.uk/ega/datasets/EGAD00001004775] and EGAD00001004776 
[https://www.ebi.ac.uk/ega/datasets/EGAD00001004776, respectively. TCGA data 
can be accessed through dbGaP accession number phs000178.v10.p8. Source data 
for figures 4-6 are provided as a Source Data file.  
 
CODE AVAILABILITY 
sysSVM is distributed as an R package under R 3.4.0 at 
https://github.com/ciccalab/sysSVM.  
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Figure 1. Cancer helper genes in 261 EACs 
a. Schematic workflow of the sysSVM algorithm.  
b. Application of sysSVM to 261 EACs. Genes with somatic damaging alterations 
(n=116,989) were extracted from 261 EACs and divided into training (known cancer 
genes, blue) and prediction (rest of altered genes, green) sets. sysSVM was trained 
on the properties of known drivers and the best models were used for prediction. All 
altered genes were scored in each patient individually and the top 10 hits were 
considered as the cancer helper genes in that patient, for a total of 2,608 helper 
genes, corresponding to 952 unique hits (red). 
c. t-distributed Stochastic Neighbour Embedding (t-SNE) plot of 116,989 altered 
genes in 261 EACs. Starting from the 34 properties used in sysSVM, a 2-D map of 
the high-dimensional data was built using Rtsne package 
(https://github.com/jkrijthe/Rtsne) in R. Curves are coloured according to the density 
of 4,091 known cancer genes (blue) used as a training set and the rest of altered 
genes are coloured according to their sysSVM score. 
d. Distribution of damaging alterations in 952 cancer helpers. Overall, these genes 
acquire 2,608 damaging alterations. 
e. Expression of helper genes in EACs where they are amplified compared to EACs 
where they are copy number neutral. FPKM values from RNA-Seq were available 
from 92 EACs. Out of the 952 helper genes, 389 had at least one amplification 
across these samples, for a total of 751 amplification events. Significance was 
assessed using the Wilcoxon rank-sum test. Lower and upper hinges and middle line 
of boxplots correspond to 25th, 75th and 50th percentiles. Upper and lower whiskers 
extend less than 1.5 times the interquartile range. 
f. Recurrence of cancer helpers across 261 EACs. Only samples acquiring 
alterations with a damaging effect are considered. 
 
Figure 2. Perturbed processes in 261 EACs 
a. Scatterplot of 51 universal pathways enriched in known drivers and helpers. For 
each pathway, the number of EACs with altered drivers and the number of EACs 
with altered drivers and helpers is shown. The size of dots is proportional to the 
additional EACs with perturbations in these pathways because of altered helpers 
only. 
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b. Schematic of the procedure to cluster EACs according to pathways enriched in 
known drivers or helpers. Enriched pathways are mapped to individual EACs and the 
Jaccard index is calculated as the proportion of shared pathways over the total 
pathways in each pair of samples (i, j). Hierarchical clustering is then performed.  
c. Clustering of 261 EACs according to pathways enriched in known drivers and 
helpers. Five clusters were identified using known drivers (1D-5D) and six using 
helpers (1H-6H). Cluster-matching coloured lines show where EACs clustered by 
pathways enriched in helpers map in the driver clusters. 
d. Mutational status of selected known drivers across 261 EACs. Drivers enriched in 
clusters of helpers are highlighted. Significance was assessed using the Fisher’s 
exact test, after correcting for False Discovery Rate (FDR). 
 
Figure 3. Features of EAC clusters driven by pathways enriched in helpers 
a. For each helper cluster (1H-6H) indicated are the molecular features (mutational 
signatures, number of genes with damaging mutations, undergoing amplification or 
deletion), the distribution of stage 2 tumours and the tobacco smoking habits of the 
patients that show significant associations with one of the six clusters of helpers. 
Enrichment in number of altered genes, tumour staging, smoking habits and cancer 
predisposition was assessed using Fisher’s exact test. Distributions of mutational 
signatures were compared using Wilcoxon rank-sum test. FDR=false discovery rate 
after correction for multiple testing. 
b. Kaplan-Meier survival curves of EACs in cluster 4H (n=37) and the rest of EACs 
(n=224). Analysis was performed using survival 
(https://github.com/therneau/survival) and survminer 
(https://github.com/kassambara/survminer) R packages with default parameters. 
Significance was measured using the log-rank test. 
 
Figure 4. Cancer helper role of E2F1 and MCM7 
a. E2F1 and MCM7 expression in EACs with amplification (n=11 samples each) 
compared to copy number neutral EACs (n=81 samples each). Significance was 
assessed by Wilcoxon rank-sum test. 
b. E2F1 and MCM7 mRNA expression in FLO-1 cells. Lower and upper hinges and 
middle line of boxplots correspond to 25th, 75th and 50th percentiles. Upper and 
lower whiskers extend less than 1.5 times the interquartile range. 
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c. Proliferation of FLO-1 cells overexpressing E2F1 or MCM7 compared to control.  
d. EdU (5-ethynyl-2'-deoxyuridine) incorporation by flow cytometry in E2F1 
overexpressing cells compared to control. Cells were separated into G1, S and G2 
phases. S phase cells were subdivided into 4 gates (S1-S4, Supplementary Figure 
9). Differences in EdU geometric mean fluorescence intensity were assessed by 
Mann-Whitney U test.  
MCM complex loading onto chromatin in MCM7 overexpressing or control cells 
through MCM7 (e) or MCM3 (f) staining. Cells were pulsed with EdU and chromatin 
was fractioned before staining for MCM7 or MCM3 to detect chromatin-bound MCM 
complex. Cells were separated into cell cycle phases using EdU and DAPI intensity. 
MCM7 or MCM3 fluorescence intensity during S phase illustrates MCM complex 
unloading from chromatin. Differences in geometric mean fluorescence intensity of 
MCM staining were assessed using Mann-Whitney U test. For (d), (e), (f) one 
representative of n=3 biological replicates is shown. Corresponding pseudocolour 
plots are in Supplementary Figure 9. 
g. MCM7 mRNA expression in MFD-1 and FLO-1 cells. 
h. qRT-PCR MCM7 expression in MFD-1 cells after transduction with a MCM7-
shRNA inducible lentiviral vector. Expression was assessed with or without 96 hours 
doxycycline treatment. 
i. Proliferation curve of MFD-1 cells with or without doxycycline-induced MCM7 
knockdown. 
For all qRT-PCR experiments, expression was relativised to β-2-microglobulin and 
normalised to FLO-1 cells. N=2 biological replicates were performed, each in 
technical triplicate. For all proliferation assays, n=2 biological replicates were 
performed, each with four technical replicates. Proliferation was assessed every 24 
hours and normalised to time zero. Mean values at 72 hours were compared by two-
tailed Student’s t-test. Error bars show standard deviation. Source data are available 
in the Source Data file. 
 
Figure 5. Cancer helper role of selected genes 
a. Function of NCOR2 as part of the nuclear receptor co-repressor complex, whose 
activity results in chromatin deacetylation and transcriptional repression. 
b. Editing of the NCOR2 gene using three pooled crRNAs where cells are transiently 
co-transfected with Cas9 protein, crRNAs and tracrRNA32. The editing efficiency was 
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measured using MiSeq. For NCOR2 two regions were sequenced, one containing 
the region targeted by crRNA1 and 2 and the other the region targeted bycrRNA3. 
For ABI2 only one amplicon was sequenced, containing the region targeted by all 
three crRNAs. The range of edited alleles and edited cells was derived considering 
the two opposite scenarios where all three crRNAs edit the same alleles/cells or 
different alleles/cells, respectively. 
c. Proliferation curve of NCOR2 or NTC edited FLO-1 cells.  
d. Manual curation of the helpers contributing to the Rho-GTPase effectors pathway. 
Heatmap indicates the number of samples with alterations in each gene. ABI2 (blue) 
and PAK1 (red) were selected for experimental validation. 
e. Induced alterations in ABI2 and PAK1 genes. Editing of ABI2 was performed and 
assessed as described for NCOR2. PAK1 mRNA expression in FLO-1 cells was 
assessed by qRT-PCR, relativised to β-2-microglobulin and normalised to control 
cells. Experiments were done in triplicate in n=2 biological replicates. 
f. Proliferation curves of FLO-1 cells after ABI2 editing or PAK1 overexpression.  
For all proliferation assays, n=3 biological replicates were performed, each with four 
technical replicates. Proliferation was assessed every 24 hours and each time point 
was normalised to time zero. Mean values at 72 hours were compared by two-tailed 
Student’s t-test. All error bars show standard deviation. Source data are available in 
the Source Data file. 
 
Figure 6. EAC cell dependence on PSMD3 alteration 
a. Heatmap of proteasome subunits predicted as helpers in 261 EACs. 
b. PSMD3 basal mRNA expression levels in FLO-1, MFD-1, OE19 and OE33 cells. 
Expression was relativised to β-2-microglobulin and normalised to FLO-1 cells.  
c. PSMD3 expression levels in MFD-1, OE19 and OE33 after transduction with a 
lentiviral vector carrying an inducible shRNA against PSMD3. Expression was 
assessed in absence of doxycycline and after 96 hours of doxycycline treatment, 
relativised to β-2-microglobulin and normalised to FLO-1 cells. 
d. Proliferation curves of MFD-1, OE19 and OE33 cells with or without doxycycline 
treatment to reduce PSMD3 expression to levels comparable to those of FLO-1 cells.  
For all proliferation assays, n=2 biological replicates were performed, each with four 
technical replicates. Proliferation was assessed every 24 hours and each time point 
was normalised to time zero. Mean values at 96 hours were compared by two-tailed 
 41 
Student’s t-test. All error bars show standard deviation. Source data are available in 
the Source Data file. 
 
Figure 7. Effect of helper alterations in Barrett’s esophagus cells 
a. Percentages of altered helper genes (661/952), known cancer genes (364/518) 
and rest of cancer unrelated genes (12,250/17,544) over the corresponding total.  
b. Percentages of damaged helper genes (261/952), known cancer genes (135/518) 
and rest of cancer unrelated genes (3,093/17,544) over the corresponding total. 
Statistical significance was assessed with two-tailed Fisher’s exact test. 
c. Distribution of 4,862 damaging alterations in 3,489 damaged genes in 82 samples 
of BE. The damaging effect of BE variants was assessed as in EAC (Methods) with 
the exception of gene gains. In this case, only ‘high gains’ defined as in the original 
publication35 were considered as damaging.  
d. Editing of ABI2, NCOR2 or TP53 in CP-A cells through nucleofection of two 
crRNAs and Cas9 protein. The editing efficiency was measured by MiSeq and 
quantified as described above. For all three genes, a single amplicon was 
sequenced. NCOR2, ABI2 and TP53 crRNAs overlapped for over 70% of their 
sequences and therefore it was not possible to assess their editing efficiency 
independently. 
e. Proliferation curves of CP-A cells after ABI2, NCOR2 or TP53 editing compared to 
control cells. For all proliferation experiments, n=3 biological replicates were 
performed, each with four technical replicates. Proliferation was assessed every 24 
hours and each time point was normalised to time zero. Mean values at 72 hours 
were compared by two-tailed Student’s t-test. Error bars show standard deviation. 
Source data are available in the Source Data file. 
